DMK Pharmaceuticals Corp
OTC:DMKPQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Concentric AB
STO:COIC
|
SE |
DMK Pharmaceuticals Corp
Revenue
DMK Pharmaceuticals Corp
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DMK Pharmaceuticals Corp
OTC:DMKPQ
|
Revenue
$3.6m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$96.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$48.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$62.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$65B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$65.2B
|
CAGR 3-Years
32%
|
CAGR 5-Years
22%
|
CAGR 10-Years
13%
|
|
DMK Pharmaceuticals Corp
Glance View
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
See Also
What is DMK Pharmaceuticals Corp's Revenue?
Revenue
3.6m
USD
Based on the financial report for Sep 30, 2023, DMK Pharmaceuticals Corp's Revenue amounts to 3.6m USD.
What is DMK Pharmaceuticals Corp's Revenue growth rate?
Revenue CAGR 5Y
-23%
Over the last year, the Revenue growth was 160%. The average annual Revenue growth rates for DMK Pharmaceuticals Corp have been -22% over the past three years , -23% over the past five years .
